GLP-1s as a Tax-Advantaged Health Investment: The 10-Year Math

Here's a framing most men miss. A 45-year-old man with a BMI of 33, pre-diabetes, elevated LDL, and blood pressure at 140/90 is staring down predictable future costs: eventual diabetes medications, eventual statin, eventual blood pressure meds, eventual possible cardiovascular event. Over the 20 years from 45 to 65, he's expected to spend tens of thousands on these medications, incur cardiovascular risk, and potentially experience reduced earning capacity as health declines.

A GLP-1 protocol, run through an HSA, priced at 2026 rates, reframes this trajectory. The medication isn't an expense. It's an investment with a measurable return — in tax-advantaged dollars, in prevented medical spending, in preserved earning capacity, and in quality-adjusted life years.

Here's the honest math.

The raw cost picture in 2026

Current pricing for GLP-1 therapy, updated for 2026 TrumpRx and direct-to-consumer options:

Source	Monthly cost	Annual cost
TrumpRx Ozempic/Wegovy (low dose)	$199	$2,388
TrumpRx Wegovy pill (low dose)	$149	$1,788
TrumpRx Zepbound (low dose)	$299	$3,588
Compounded (telehealth, budget)	$150–$250	$1,800–$3,000
Insurance-covered brand (typical copay)	$25–$100	$300–$1,200
Full cash brand (pre-TrumpRx pricing)	$900–$1,400	$10,800–$16,800

For this analysis, assume our representative man uses TrumpRx or equivalent direct-to-consumer pricing: $2,500/year average over a 10-year period, accounting for dose-level mix, maintenance vs. active-loss phases, and price trajectory (prices projected to decline toward $245/month for injectables within 2 years of TrumpRx launch).¹

The HSA tax multiplier

Assuming the man is in the 24% federal bracket + 5% state = 29% effective tax rate:

• Pre-HSA spending: $25,000 over 10 years, post-tax.
• Effective pre-tax cost of post-tax spending: approximately $35,200 (needed to generate $25,000 after tax).
• HSA spending: $25,000 pre-tax dollars.
• Net 10-year tax savings: approximately $10,200.

For higher-income men (32–37% marginal bracket + state), tax savings scale to $13,000–$16,000 over 10 years.

The prevented-spending picture

The more important math: what does obesity cost a 45-year-old over the next 20 years if not addressed?

Documented obesity-related healthcare spending for men with BMI ≥30:

• Type 2 diabetes treatment: $9,000–$15,000/year at full disease state (medication, monitoring, complications).
• Statin therapy plus cardiovascular management: $500–$3,000/year.
• Hypertension management: $300–$1,500/year.
• Obstructive sleep apnea treatment: $1,500–$3,000/year (CPAP + follow-up).
• Joint/orthopedic issues from excess weight: highly variable; knee replacement alone is $30,000–$50,000.
• Cardiovascular event (MI, stroke) cumulative cost: $50,000–$200,000+ depending on severity.

Not every man progresses through all these. But for a man with current risk factors (pre-diabetes, elevated BP, elevated LDL, BMI 33), the conditional probabilities of developing diabetes, needing statin therapy, or experiencing a cardiovascular event over the next 20 years are substantial — literature estimates for this risk profile put combined lifetime risk of major adverse cardiovascular events above 30%.

The cardiovascular value of the SELECT data

The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events (MACE) with semaglutide 2.4 mg in men with obesity and established cardiovascular disease.² For primary prevention (men without established disease), the absolute benefit is smaller but still meaningful.

Framed in dollars: a 20% reduction in lifetime cardiovascular event risk, for a man with moderate baseline risk, represents prevented future spending of roughly $15,000–$40,000 in expected value over 20 years. The cardiovascular benefit alone often exceeds the medication cost.

The preserved-earning picture

Often-overlooked: health status affects earning capacity. Men who develop diabetes, cardiovascular disease, or significant metabolic dysfunction in their 50s experience:

• Higher rates of disability and early retirement.
• Reduced productivity (absenteeism, presenteeism).
• Higher insurance premiums.
• Reduced ability to sustain demanding careers into their 60s.

A man who arrives at 65 in better health earns more in his final working decade than a man whose health has declined. The difference is sometimes six-figure — a 60-year-old man with robust health can choose when to retire; a 60-year-old managing diabetes and cardiovascular disease often cannot.

The testosterone side benefit

Men who normalize testosterone through weight loss (ENDO 2025: 53% → 77% normalization over 18 months on GLP-1 therapy³) avoid the cost of TRT: $75–$200/month, or $900–$2,400/year, for men who would otherwise pursue replacement therapy to address low-T symptoms.

Over 10 years, that's $9,000–$24,000 of avoided TRT spending for men whose weight-loss-driven testosterone recovery eliminates the need.

The 10-year integrated picture

These are expected values with individual variance. Not every man would otherwise develop diabetes, require TRT, or experience earning-capacity reduction. But in aggregate for the population of men who start GLP-1 therapy from this risk profile, the mathematics suggest the treatment is a positive-expected-return investment even before considering quality-of-life benefits.

The HSA investment compound

For men with robust HSAs who can cash-flow current medical expenses from other sources, the maximum tax-advantaged play is:

1. Max out HSA contributions annually.
2. Pay current medical expenses from regular funds (save receipts).
3. Invest HSA funds in index funds within the HSA.
4. Let HSA grow tax-free for decades.
5. In retirement, reimburse yourself for past qualified medical expenses with tax-free HSA withdrawals.

This "receipt banking" approach lets HSA dollars compound for 20+ years while still being available for future tax-free medical spending. For a man able to execute this strategy, the HSA becomes a stealth IRA with triple-tax-advantaged status (deductible contributions, tax-free growth, tax-free qualified withdrawals).

For GLP-1 spending specifically, the math is straightforward: $4,800/year contributed to HSA + invested in index funds for 20 years at 7% real return = ~$210,000 tax-free. That's meaningful retirement health-spending capacity.

The underconsidered downsides

Honest accounting requires acknowledging costs that don't show up on spreadsheets:

• Time cost of protocol management. Labs, follow-ups, titration periods, side effect management. Not trivial.
• Side effect tolerance. 30% of men have meaningful GI side effects during titration.
• Long-term safety uncertainty. GLP-1 class has 20+ years of diabetes safety data but only ~5 years of weight-loss-dose safety data. Future risks may emerge.
• Medication dependency. For most men who hold weight off, continuous therapy is needed. This is itself a trade-off.
• Opportunity cost of the money. $2,500/year invested instead at 7% over 10 years = $34,500. You're forgoing that return to fund medication.

A fair analysis accounts for all of these. The net-positive expected value conclusion still holds in most risk profiles, but it's a calculation, not a slam-dunk.

Who the math works best for

GLP-1 therapy has the strongest expected-return case for men who:

• Are 40+ years old with elevated cardiometabolic risk factors.
• Have HSA access through a high-deductible health plan.
• Are in higher tax brackets (tax savings scale with marginal rate).
• Have family history of diabetes, cardiovascular disease, or metabolic conditions.
• Are in careers that benefit from sustained health and energy into their 60s.
• Plan to use the tax-advantaged approach for 5+ years.

Who the math works less well for

• Younger men (25–35) with lower baseline cardiovascular risk — the prevention ROI is smaller.
• Men with insurance that already covers GLP-1s with low copays — the HSA savings don't add much.
• Men who don't have HSA access — FSA still works but less powerfully.
• Men at normal BMI using GLP-1s cosmetically — these uses don't qualify for HSA/FSA and don't have the prevention ROI.
• Men with complicated side effect profiles who end up discontinuing after a year.

Compared to other tax-advantaged health investments

Honest comparison to the alternatives a man in this demographic might consider:

Investment	Annual cost	Expected 10-year ROI
GLP-1 via HSA (this article)	$2,500	Substantial health + tax return
Personal trainer 2x/week	$5,000–$8,000	Moderate if consistent
Premium gym + meal prep service	$3,500–$6,000	Moderate if consistent
CPAP treatment for diagnosed OSA	$500–$1,500	Very high (if indicated)
Annual comprehensive physical + labs	$300–$800	Very high (for everyone)
TRT (if clinically indicated)	$900–$2,400	High (if indicated)

Among the options, GLP-1 therapy for the right man has one of the strongest combined health-and-tax return profiles available. It's not a substitute for training and nutrition discipline — it amplifies them.

The bottom line

Run through an HSA at 2026 pricing, GLP-1 therapy for a middle-aged man with cardiometabolic risk factors is one of the best tax-advantaged health investments available. Direct medication spending, tax savings, prevented future medical costs, cardiovascular benefit, and preserved earning capacity add up to a substantially positive expected return over 10+ years.

This isn't a case for treating GLP-1s as a general wellness tool. It's a case for recognizing them as legitimate prevention — for the men whose risk profile actually justifies the treatment — and running the spending tax-efficiently when you do commit.

Spend the money deliberately. Document it properly. Use the HSA. Keep the receipts. And reframe the $250/month as health investment rather than monthly expense. The 10-year math makes sense.